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Abstract
Background: Increasing evidence indicates that the interaction between the CXC chemokine receptor-4 (CXCR4)
and its ligand CXCL12 is critical in the process of metastasis that accounts for more than 90% of cancer-related
deaths. Thus, novel agents that can downregulate the CXCR4/CXCL12 axis have therapeutic potential in inhibiting
cancer metastasis.
Methods: In this report, we investigated the potential of an agent, plumbagin (5-hydroxy-2-methyl-1, 4-
naphthoquinone), for its ability to modulate CXCR4 expression and function in various tumor cells using Western
blot analysis, DNA binding assay, transient transfection, real time PCR analysis, chromatin immunoprecipitation, and
cellular migration and invasion assays.
Results: We found that plumbagin downregulated the expression of CXCR4 in breast cancer cells irrespective of
their HER2 status. The decrease in CXCR4 expression induced by plumbagin was not cell type-specific as the
inhibition also occurred in gastric, lung, renal, oral, and hepatocellular tumor cell lines. Neither proteasome
inhibition nor lysosomal stabilization had any effect on plumbagin-induced decrease in CXCR4 expression. Detailed
study of the underlying molecular mechanism(s) revealed that the regulation of the downregulation of CXCR4 was
at the transcriptional level, as indicated by downregulation of mRNA expression, inhibition of NF-B activation, and
suppression of chromatin immunoprecipitation activity. In addition, using a virtual, predictive, functional
proteomics-based tumor pathway platform, we tested the hypothesis that NF-B inhibition by plumbagin causes
the decrease in CXCR4 and other metastatic genes. Suppression of CXCR4 expression by plumbagin was found to
correlate with the inhibition of CXCL12-induced migration and invasion of both breast and gastric cancer cells.
Conclusions: Overall, our results indicate, for the first time, that plumbagin is a novel blocker of CXCR4 expression
and thus has the potential to suppress metastasis of cancer.
Background
Metastasis is a highly complex and non-spontaneous
process that generally affects vital organs such as brain,
lung, liver, bone or lymph nodes [1-3] in the later stages
of cancer progression. At present, there are no approved
drugs that can specifically target the metastatic process
[4,5], and little is known about the molecular mechan-
ism(s) regulating the process of metastasis [5]. Chemo-
kines are a large family of small chemotactic cytokines
that regulate multiple biological processes such as leu-
kocyte trafficking, hematopoiesis, adhesion, and angio-
genesis [6-8]. Based on the position of the first two
conserved cysteine residues, the chemokines can be clas-
sified into four subfamilies, CXC, CC, C, and CX3C, and
act on leukocytes via selective membrane-bound G pro-
tein-coupled receptors [2,3].
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CXCR4 signaling cascade plays a crucial role in cancer
proliferation, migration and metastasis [9]. CXCR4 is
expressed by various types of tumor cells, including
breast [10], colorectal [11], gastric [12], ovarian [13],
pancreatic [14], prostate [15], lung [16], melanoma [17],
and brain [18] tumor cells. The SDF-1a/CXCR4 attrac-
tion leads breast cancer cells to leave the circulation and
migrate into organs that express large amounts of che-
mokines, where the cancer cells proliferate, induce
angiogenesis and form metastatic tumors [7,19]. As
CXCR4 expression has been correlated with poor overall
survival rate in patients with breast cancer [20], and col-
orectal cancer [21], CXCR4 has been considered as a
potential therapeutic target for inhibiting cancer metas-
tasis [22].
In the present report, we studied the effect of plumba-
gin (5-hydroxy-2-methyl-1, 4-naphthoquinone, an analo-
gue of vitamin K3) as a novel regulator of the CXCL12/
CXCR4 signaling axis. Plumbagin, a naturally occurring
yellow pigment predominantly found in the plants of
the Plumbaginaceae, Ancestrocladaceae,a n dDionco-
phyllaceae families, has been reported to exhibit signifi-
cant anti-proliferative, pro-apoptotic, chemopreventing
and radiosensitizing activities in different tumor cells
and animal models [23-30]. Because CXCR4 is known
to mediate proliferation, invasion and metastasis of
tumor cells, we postulated that plumbagin may modu-
late the expression of CXCR4 and inhibit tumor cell
invasion. Our results demonstrate, for the first time,
that plumbagin can downregulate CXCR4 expression in
various tumor cells, including HER2-overexpressing
breast cancer cells, and this could be through its inhibi-
tion of NF-B activation. We also found that plumbagin
can significantly inhibit CXCL12-induced migration and
invasion of breast and gastric tumor cells.
Alongside testing the effects of plumbagin experimen-
tally in various tumor cells, we also tested the hypoth-
esis of plumbagin-mediated NF-B inhibition as the key
reason for the reduction in CXCR4 and other metastatic
genes, in a virtual, predictive, tumor cell system. The
virtual epithelial tumor cell platform on which predictive
NF-B inhibition studies were conducted is a compre-
hensive integrated functional proteomics based, dynamic
representation of the pathways representing the key can-
cer phenotypes of proliferation, apoptosis, angiogenesis,
metastasis and conditions of tumor microenvironment
including tumor-associated inflammation [31-33]. In this
virtual tumor cell system, we can manipulate any pro-
tein or gene by over-expression or knockdown and get
quantitative readouts and insights on the impact of this
change on the various markers in the system. This pre-
dictive analysis helps in reconfirming the experimental
hypothesis and giving mechanistic insights into under-
standing the trends in biomarker and phenotype
changes. This novel approach has facilitated the analysis
of the impact of plumbagin on metastatic genes based
on the premise that this quinone mediates its affects pri-
marily via modulation of NF-B activation. The combi-
nation of predictive experiments coupled with guided
experimental validations provide a more integrated ana-
lysis and a better understanding of the efficacy and
mechanisms of action of specific anti-cancer drugs on
physiological endpoints.
Methods
Reagents
Plumbagin, Tris, glycine, NaCl, SDS, lactacystin, and
chloroquine were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Plumbagin was dissolved in dimethyl-
sulfoxide as a 20 mM stock solution and stored at 4°C.
Further dilution was done in cell culture medium. RPMI
1640, DMEM, fetal bovine serum (FBS), 0.4% trypan
blue vital stain, antibiotic-antimycotic mixture, and
HRP-conjugated secondary antibodies were obtained
from Invitrogen (Carlsbad, CA, USA). Antibodies against
CXCR4 and HER2 were obtained from Abcam (Cam-
bridge, MA, USA). CXCL12 was purchased from Pro-
Spec-Tany TechnoGene Ltd. (Rehovot, Israel).
Cell Lines
Human breast cancer MDA-MB-231, BT474, and oral
adenosquamous carcinoma CAL27 cells were obtained
from American Type Culture Collection (Manassass,
VA, USA).
AGS, MKN45, and SNU16 (gastric cancer) cells were
kindly provided by Prof. Patrick Tan, DUKE-NUS Grad-
uate Medical School, Singapore. Hep3B (hepatocellular
carcinoma) cells were kindly provided by Prof. Hui Kam
Man, National Cancer Centre, Singapore. 786-O (renal
cell carcinoma) cells were kindly provided by Dr. John
Yuen, Singapore General Hospital, Singapore. H1299
(lung adenocarcinoma) cells were kindly provided by
Prof. Bharat B. Aggarwal, M.D. Anderson Cancer Cen-
ter, Houston, TX, USA. MDA-MB-231, AGS, MKN45,
SNU16, 786-O, and H1299 cells were cultured in RPMI
1640 medium with 10% FBS, 100 U/mL penicillin, and
100 μg/mL streptomycin. BT474 cells were cultured in
DMEM F12 medium with 10% FBS, 100 U/mL penicil-
lin, and 100 μg/mL streptomycin. Hep3B cells were cul-
tured in DMEM supplemented with 10% FBS, 100 U/
mL penicillin, and 100 μg/mL streptomycin. CAL27
cells were cultured in DMEM containing 10% FBS, and
1 mM pyruvate, 100 U/mL penicillin, and 100 μg/mL
streptomycin and were maintained at 37°C in an atmo-
sphere of 5% CO2-95% air.
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For detection of CXCR4 and HER2, plumbagin-treated
whole-cell extracts were lysed in lysis buffer (20 mM
Tris (pH 7.4), 250 mM NaCl, 2 mM EDTA (pH 8.0),
0.1% Triton X-100, 0.01 mg/mL aprotinin, 0.005 mg/mL
leupeptin, 0.4 mM PMSF, and 4 mM NaVO4). Lysates
were then spun at 14,000 rpm for 10 min to remove
insoluble material and resolved on a 10% SDS gel. After
electrophoresis, the proteins were electrotransferred to a
nitrocellulose membrane, blocked with 5% nonfat milk
to minimize non-specific binding, and probed with anti-
CXCR4 or HER2 antibodies (1:3000) overnight at 4°C.
The blot was washed, exposed to HRP-conjugated sec-
ondary antibodies for 2 h, and the CXCR4/HER2
expression was detected by chemiluminescence emission
(ECL; GE Healthcare, Little Chalfont, Buckinghamshire,
UK). The densitometric analysis of the scanned blots
was done using Image J software and the results are
expressed as fold change relative to the control.
Nuclear extract preparation
Nuclear extracts were prepared at various time points
after treatment for subsequent NF-BD N A - b i n d i n g
activity assay. Cell nuclear fractions were extracted
using a nuclear extraction kit (Active Motif, Carlsbad,
CA, USA). Briefly, cells were washed, collected in ice-
cold PBS in the presence of phosphatase inhibitors, and
then centrifuged at 300 g for 5 min. Cell pellets were
resuspended in a hypotonic buffer, treated with deter-
gent, and centrifuged at 14,000 g for 30 s. After collec-
tion of the cytoplasmic fraction, the nuclei were lysed,
and nuclear proteins were solubilized in lysis buffer and
protein concentrations were determined by the Bradford
protein assay (Bio-Rad Laboratories, Hercules, CA,
USA).
NF-B DNA-binding activity assay
NF-B DNA-binding activity was analyzed using the
TransAM NF-B p65 transcription factor assay kit
(Active Motif, Carlsbad, CA, USA), following the manu-
facturer’s instructions. Briefly, nuclear extracts (5 μg)
from plumbagin-treated cells were incubated in a 96-
well plate coated with oligonucleotide containing the
NF-B consensus-binding sequence 5’-GGGACTTTCC-
3’.B o u n dN F - B was then detected by a specific pri-
mary antibody. An HRP-conjugated secondary antibody
was then applied to detect the bound primary antibody
a n dp r o v i d e dt h eb a s i sf o rc o lorimetric quantification.
The enzymatic product was measured at 450 nm with a
microplate reader (Tecan Systems, San Jose, CA, USA).
NF-B luciferase reporter assay
MDA-MB-231 cells were plated in 96-well plates with 1
×1 0
4 cells per well in 10% FBS-supplemented RPMI
medium. After overnight incubation, the cells were
transfected with the NF-B reporter plasmid linked to a
luciferase gene or with the dominant-negative IBa
(IBa-DN) plasmid. NF-B luciferase plasmid was
obtained from Stratagene (La Jolla, CA). Transfections
were done according to the manufacturer’sp r o t o c o l s
using FuGENE-6 (Roche). At 24 h post-transfection,
cells were treated with indicated concentrations of
plumbagin for 2 h and then washed and lysed in lucifer-
ase lysis buffer (Promega), and the luciferase activity was
measured with a luminometer using a luciferase assay
kit (Promega) and was normalized to b-galactosidase
activity. All the experiments were done in triplicates and
repeated two or more times.
RNA extraction and Real-time PCR analysis
Total RNA was extracted using the Trizol reagent (Invi-
trogen, Carlsbad, CA, USA), according to the manufac-
turer’s instructions. Reverse transcription (RT) was then
carried out at 37°C for 1 h. Each RT reaction contains 1
μgo ft o t a lR N A ,1 ×R Tb u f f e r ,5m MM g C l 2, 425 μM
each of dNTPs, 2 μM random hexamers, 0.35 U/μL
RNase inhibitor, 1.1 U/μL MultiScribe reverse transcrip-
tase and made up to 10 μL with sterile water. The rela-
tive expression of CXCR4 was then analyzed using
quantitative RT-PCR (ABI PRISM 7500, Applied Biosys-
tems, Foster City, CA, USA) with 18sRNA as an internal
control. Primers and probes for human CXCR4 and
18sRNA were purchased as Assays-on-Demand kits
(Applied Biosystems).
Chromatin immunoprecipitation (ChIP) assay
The cells were processed for the ChIP assay as per the
protocol described by Saccani et al., 2002 [34]. The anti-
body used for the ChIP was NF-kB (p65)Ab (Santa Cruz
Biotechnology, SantaCruz, CA, USA). The sequence for
human CXCR4 gene promoter was as follows: sense pri-
mer, 5’-ACAGAGAGACGCGTTCCTAG-3’ and anti-
sense primer, 5’-AGCCCAGGGGACCC TGCTG-3’.
The PCR products were analyzed on 2% agarose gel
electrophoresis and documented.
Wound Healing Assay
MDA-MB-231 and AGS cells were treated with 5 μM
plumbagin in RPMI medium containing 1% serum.
Before plating the cells, two parallel lines were drawn at
the underside of the wells, to serve as fiducial marks
demarcating the wound areas to be analyzed. Prior to
inflicting the wound, the cells should be fully confluent.
The growth medium was aspirated off and replaced by
calcium-free PBS to prevent killing of the cells at the
edge of the wound by exposure to high calcium concen-
trations before two parallel scratch wounds were made
perpendicular to the marker lines with a sterile 1000-μL
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was then changed to medium with or without plumba-
gin. After incubation for 6 h, the growth medium was
then changed to basal medium with or without
CXCL12. 24 h later, the wounds were observed using
bright field microscopy and multiple images were taken
at areas flanking the intersections of the wound and the
m a r k e rl i n e sa tt h es t a r ta n de n do ft h ee x p e r i m e n t .
Gap distance of the wound was measured at three dif-
ferent sites using Photoshop software, and the data were
normalized to the average of the control. Graphs were
plotted against the percentage of migration distance the
cells moved before and after treatment, normalized to
control.
Invasion assay
The in vitro invasion assay was performed using Bio-
Coat Matrigel invasion assay system (BD Biosciences,
San Jose, CA, USA), according to the manufacturer’s
instructions. MDA-MB-231 and AGS cells (2 × 10
5
cells) were suspended in serum-free RPMI medium and
seeded into the Matrigel transwell chambers consisting
of polycarbonate membranes with 8-μmp o r e s .A f t e r
pre-incubation with or without plumbagin for 6 h, the
transwell chambers were then placed into appropriate
wells of a 24-well plate, in which either the basal med-
ium only or basal medium containing CXCL12 had
been added. After incubation for 24 h, the upper sur-
faces of the transwell chambers were wiped with cotton
swabs and the invading cells were fixed and stained with
crystal violet solution. The invading cell numbers were
counted in five randomly selected microscope fields.
Predictive Experiments on Virtual Tumor Cell
Predictive experiments were performed using the phy-
siologically aligned and qualified Virtual Tumor Cell
technology (Cellworks Group Inc (CWG), CA, USA
[31,35]. The Cellworks Tumor cell platform provides a
dynamic and transparent view of tumor cell physiology
at the functional proteomics abstraction level. The plat-
form’s open-access architecture provides a framework
for different ‘what-if’ analysis and studies in an auto-
mated high-throughput methodology.
Platform description
The virtual Tumor Cell Platform consists of a dynamic
and kinetic representation of the signaling pathways
underlying tumor physiology at the bio-molecular level.
All the key relevant protein players and associated gene
and mRNA species are comprehensively included in the
system with their relationship quantitatively represented.
Pathways and signaling for different cancer phenotypes
comprise 75 major signaling networks with more than
3500 intracellular molecules and 12000 cross talks and
links. The platform includes important signaling path-
ways comprising growth factors like EGFR, PDGFRA,
FGFR, c-MET, VEGFR and IGF-1R, cell cycle regulators,
mTOR signaling, p53 signaling cascade, cytokine path-
ways like IL1, IL4, IL6, IL12, TNF; TGF-b, hypoxia
mediated regulation, angiogenic promoters, lipid media-
tors and tumor metabolism (Figure 1B). It has a wide
coverage of kinases and transcription factors associated
with tumor physiology network. The platform has been
correlated against an extensive set of pre-defined in
vitro and in vivo studies.
The starting control state of the system is based on
normal epithelial cell physiology that is non-tumori-
genic. The user can control the transition of the normal
system to a neoplastic disease state aligning with specific
tumor mutation profiles. This is accomplished as an
example through over-expression of the tumorigenic
genes like EGFR, IGF-1R; knock-downs of the tumor-
suppressors like p53, PTEN; and increased states of
hypoxia and oxidative stress. Knockdowns or over-
expressions of biomolecular species can be done at the
expression or activity levels. When a drug is introduced
into the system with a specific mechanism of action, the
drug concentration in the virtual experiments is expli-
c i t l ya s s u m e dt ob ep o s tA D M E (Absorption, Distribu-
tion, Metabolism, and Excretion).
Predictive Study Experimental Protocol
The virtual Tumor cell is simulated in the proprietary
Cellworks computational backplane and initialized to a
control state wherein all molecules attain the control
steady state values, following which the triggers are
introduced into the system.
The experiments were conducted in two different dis-
ease state baselines corresponding to MDA-MB-231
human breast cancer cell line and AGS human gastric
cancer cell line. MDA-MB-231 baseline has an over-
expression of BRAF, is KRASd o m i n a n t ,P 5 3m u t a n t
and CDKN2A depleted cell line. AGS is a PI3KA over-
expressed, KRAS dominant, b-catenin over-expressed
and CDH1 (E-cadherin) depleted cell line. These base-
lines for MDA-MB-231 and AGS cell lines were created
by overlaying the specific mutations on the control sys-
tem to attain dynamic disease state. On these cell lines,
NF-B activation was inhibited by 50% and 100% to
emulate plumbagin mediated NF-B inhibition. The
experiment is simulated and the system is allowed to
dynamically settle to a different steady-state from the
baseline and the biomarker trends evaluated as percen-
tage change from baseline values with respect to 50%
and 100% inhibition of NF-B activation. The impact of
NF-B inhibition in these virtual cell lines on CXCR4,
VEGFA and other metastatic markers was assayed and
compared with experimental data for plumbagin.
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Page 4 of 14Figure 1 Predictive In Silico Virtual tumor platform generated results. A, The chemical structure of plumbagin. B, The figure illustrates a
high-level view of the maze of interactions and cross-talks present in the Virtual Tumor Cell platform. C, The figure illustrates the percentage
reduction in CXCR4 and VEGFA with 50% and 100% inhibition of NF-B in MDA-MB-231 (breast cancer) and AGS (gastric cancer) aligned virtual
tumor cells. D, The figure illustrates the percentage reduction in metastatic tumor markers- CDH1 and Cathepsin B with 50% and 100% inhibition
of NF-B activation in the two tumor baselines.
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The experiments were carried out in triplicates and
repeated at least twice. Data are expressed as the mean
± S.E.M. In all figures, vertical error bars denote the S.E.
M. The significance of differences between groups was
evaluated by Student’s t-test and one way analysis of
variance, (ANOVA). A p value of less than 0.05 was
considered statistically significant.
Results and Discussion
The present study was designed to investigate the effect
of plumbagin (with structure shown in Figure 1A) on
CXCR4 expression and also on cellular migration and
invasion in various tumor cells.
Predictive analysis of inhibition of NF-B activation in
tumor cells
To test whether inhibition of NF-B activation is pri-
marily causing the plumbagin-mediated impact on meta-
static markers in tumor cells, we tested this hypothesis
in the virtual tumor cells aligned to a breast cancer cell
line MDA-MB-231 and a gastric cell line cell line AGS
(Figure 1B). The inhibition of NF-B activation by 50%
and 100% leads to marked decrease in the expression of
CXCR4 and slight decrease in VEGF expression in both
these cell line profiles, as depicted in Figure 1C. These
predictive results corroborate with the experimental
data and support the hypothesis that plumbagin effects
on metastatic phenotypes in tumor cells are mainly
through inhibition of NF-B activation. Additional
metastatic markers such as Cathepsin B and E-Cadherin
were also monitored. A predictive increase in CDH1
and a decrease in Cathepsin B (Figure 1D) also indicate
that plumbagin would have a good impact on inhibiting
metastasis phenotype in tumor cells.
Plumbagin suppresses the expression of CXCR4 protein in
breast cancer cells
Several lines of evidence implicate the role of CXCR4 in
breast cancer metastasis [19,36]. Muller et al. found that
motility and migration of breast cancer cells can be
induced when they are exposed to their ligand, CXCL12
[36]. Also, breast cancer metastasis can be inhibited by
silencing CXCR4 [37]. Hence, we first investigated the
effect of plumbagin on CXCR4 expression in breast can-
cer MDA-MB-231 cells. When MDA-MB-231 cells were
incubated with different concentrations of plumbagin
f o r6ho rw i t h5μM of plumbagin for different times,
plumbagin suppressed the expression of CXCR4 in a
dose- and time-dependent manner (Figures 2A and 2B),
confirming the predictive trends as in Figure 1C. HER2
overexpression has been linked with metastasis of breast
cancer [38]. Furthermore, HER2 has been shown to
induce the expression of CXCR4 in breast cancer cells
[38]. Hence, we also investigated the effect of plumbagin
in BT474 cells that express high endogenous levels of
HER2 [39]. When BT474 cells were incubated with dif-
ferent concentrations of plumbagin for 6 h, the expres-
sion of CXCR4 was found to be down-regulated in a
dose-dependent manner (Figure 2C). Since HER2
enhances the expression of CXCR4 by stimulating
Figure 2 Plumbagin suppresses CXCR4 expression in breast
cancer cells. A, Plumbagin suppresses CXCR4 levels in a dose-
dependent manner. MDA-MB-231 cells (1 × 10
6) were treated with
the indicated concentrations of plumbagin for 6 h. Whole-cell
extracts were then prepared, and 30 μg of protein was resolved on
SDS-PAGE, electrotransferred onto nitrocellulose membranes, and
probed for CXCR4. The same blots were stripped and reprobed with
b-actin antibody to show equal protein loading. B, Plumbagin
suppresses CXCR4 levels in a time-dependent manner. MDA-MB-231
cells (1 × 10
6) were treated with 5 μM plumbagin for the indicated
times, after which Western blotting was done as described above.
The same blots were stripped and reprobed with b-actin antibody
to show equal protein loading. C, Plumbagin suppresses CXCR4
levels in HER2 overexpressing BT474 cells. BT474 cells (1 × 10
6) were
treated with the indicated concentrations of plumbagin for 6 h.
Whole-cell extracts were then prepared, and 30 μg of protein was
resolved on SDS-PAGE, electro-transferred onto nitrocellulose
membranes, and probed for CXCR4. The same blots were stripped
and reprobed with b-actin antibody to show equal protein loading.
D, Effect of plumbagin on HER2 expression in BT474 cells. BT474
cells (1 × 10
6) were treated with the indicated concentrations of
plumbagin for 6 h, after which Western blotting for HER2 was done
as described above. The same blots were stripped and reprobed
with b-actin antibody to show equal protein loading. The
representative results of three independent experiments are shown.
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[40], we also examined whether plumbagin downregu-
lates CXCR4 expression through regulation of HER2
expression. For this, HER2-overexpressing BT474 cells
were incubated with different concentrations of plumba-
gin for 6 h and then examined for HER2 expression by
Western blot analysis using specific antibodies. We
found that HER2 expression was minimally affected
after plumbagin treatment (Figure 2D), thus suggesting
that downregulation of CXCR4 expression by plumbagin
is not due to modulation of HER2 expression.
Plumbagin downregulates CXCR4 in different
tumor cell types
Up to this point, all of the afore-mentioned studies were
carried out with breast cancer cell lines. However,
CXCR4 is known to be overexpressed in a wide variety
of tumor cells [41]. Hence, we carried out the same
experiment to find out whether plumbagin downregu-
lates expression of CXCR4 in gastric (AGS, MKN45,
and SNU16) cancer cell lines, which has never been
investigated before. Cells were treated with 5 μM plum-
bagin for 6 h before assessing the resultant effect on
CXCR4 expression. Figure 3 clearly demonstrates that
plumbagin substantially downregulated CXCR4 expres-
sion in all three gastric cancer cell lines, also confirming
the predictive results from the virtual AGS cell line
(Figure 1C). Upon further extension of studying the
effect of plumbagin on CXCR4 expression in lung ade-
nocarcinoma (H1299), renal cell carcinoma (786-O),
oral adenosquamous carcinoma (CAL27), hepatocellular
carcinoma (Hep3B) tumor cell lines, we also found that
plumbagin dramatically downregulated the CXCR4
expression in all these cell lines (Figure 3). This showed
convincingly that CXCR4 downregulation by plumbagin
is not cell type-specific.
Downregulation of CXCR4 expression by plumbagin is
not mediated through its degradation
Because plumbagin could downregulate CXCR4 expres-
sion by enhancing its degradation, and CXCR4 has been
shown to undergo ubiquitination at its lysine residue
followed by degradation [42,43], we next investigated
the possibility that plumbagin may enhance the rate of
CXCR4 degradation via the activation of proteasomes.
To determine this, we examined the ability of lactacys-
tin, a proteasome inhibitor, to block plumbagin -induced
d e g r a d a t i o no fC X C R 4 .M D A - M B - 2 3 1c e l l sw e r ep r e -
treated with lactacystin for 1 h before being exposed to
plumbagin. As shown in Figure 4A, lactacystin had no
effect on plumbagin-induced degradation of CXCR4,
suggesting that this is an unlikely basis for the suppres-
sion of CXCR4 expression by plumbagin.
We also examined the ability of chloroquine, a lysoso-
mal inhibitor, to block plumbagin-induced degradation
of CXCR4, as CXCR4 has been shown to undergo
ligand-dependent lysosomal degradation [43]. The cells
were pretreated with chloroquine for 1 h before expo-
sure to plumbagin. Our results showed that chloroquine
at 200 μM only slightly prevented the degradation of
CXCR4 (Figure 4B), suggesting that this was arguably
not the primary pathway for suppression of expression
of CXCR4.
Downregulation of CXCR4 by plumbagin occurs at the
transcriptional level
Since plumbagin did not downregulate CXCR4 expres-
sion by enhancing its degradation, we investigated
whether suppression occurs at the transcriptional level
instead. Cells were treated with plumbagin for different
times and then the mRNA was extracted for analysis by
real-time PCR. As shown in Figure 4C, plumbagin
induced the downregulation of CXCR4 mRNA in a
time-dependent manner.
Plumbagin suppresses constitutive activation of NF-Bi n
MDA-MB-231 cells
The promoter of CXCR4 is known to contain several
NF-B binding sites [44]. In addition, HER2 oncogene
has been shown to activate NF-B in breast cancer cells
[45]. Thus it is possible that plumbagin manifests its
effect on CXCR4 by suppressing NF-B activation. We
used a DNA-binding assay to assess the effect of plum-
bagin on constitutive NF-Ba c t i v a t i o ni nM D A - M B -
231 cells, and found that the treatment with plumbagin
can suppress constitutive NF-B activation in a dose-
dependent manner (Figure 4D). This result suggests that
plumbagin may downregulate CXCR4 expression
through inhibition of NF-B activation. However, DNA
binding alone is not always associated with NF-B-
dependent gene transcription [46], suggesting that addi-
tional regulatory steps are involved. Subsequent results
also indicated that plumbagin inhibited NF-Br e p o r t e r
activity in a dose-dependent manner in MDA-MB-231
cells (Figure 4E). This hypothesis was also tested simul-
taneously through the virtual system and confirms that
inhibition of NF-B plays a pivotal role in plumbagin-
mediated reduction of CXCR4 (Figure 1C) and other
metastatic markers (Figure 1D).
Plumbagin inhibits binding of NF-B to the CXCR4
promoter
Whether the downregulation of CXCR4 by plumbagin in
MDA-MB-231 cells was due to suppression of NF-B
activation in vivo was examined by a ChIP assay target-
ing NF-B binding in the CXCR4 promoter. We found
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CXCR4 promoter (Figure 4F), thereby indicating that
plumbagin inhibits CXCR4 expression by suppressing
NF-B binding to the CXCR4 promoter.
Plumbagin suppresses CXCL12-induced breast cancer cell
migration and invasion
Whether downregulation of CXCR4 by plumbagin cor-
relates with breast cancer cell migration was examined
using an in vitro wound healing assay. We found that
breast cancer cells migrated faster under the influence
of CXCL12 and this effect was abolished on treatment
with plumbagin (Figure 5A). Using an in vitro invasion
assay, we also found that CXCL12 significantly induced
the invasion of breast cancer MDA-MB-231 cells and
that plumbagin significantly abrogated the invasive activ-
ity (Figure 6A).
Plumbagin inhibits CXCL12-induced gastric cancer cell
migration and invasion
In addition, the CXCL12/CXCR4 signaling has been
shown to play a critical role in gastric cancer metastasis
[12]. Using an in vitro wound healing assay, we found
that gastric cancer AGS cells migrated faster under the
influence of CXCL12 and this effect was abolished on
treatment with plumbagin (Figure 5B). To elucidate
further the effect on plumbagin on CXCL12-induced
cell invasion, we also found that treatment of plumbagin
suppressed CXCL12-induced invasion of AGS cells
(Figure 6B). We also found that plumbagin also downre-
gulated the expression of both mRNA (Figure 6C) and
protein (Figure 6D) for CXCR4 in a time-dependent
manner in AGS cells.
Conclusions
The aim of the present study was to determine whether
the anti-cancer agent, plumbagin, can suppress the
expression and function of CXCR4, a chemokine recep-
tor that has been closely linked with tumor cell prolif-
eration, invasion, and metastasis. Our results indicate
for the first time that plumbagin downregulated
the expression of CXCR4 in different types of tumor
cells, irrespective of the cell type and HER2 status. For
example, plumbagin was found to suppress CXCR4
Figure 3 Plumbagin downregulates CXCR4 in different tumor cell types. Gastric cancer (AGS, MKN45, and SNU16), lung
adenocarcinoma (H1299), renal cell carcinoma (786-O), oral adenosquamous carcinoma (CAL27), hepatocellular carcinoma (Hep3B)
cells were incubated with 5 μM plumbagin for 6 h. Whole-cell extracts were prepared and analyzed by Western blot analysis using antibody
against CXCR4. The same blots were stripped and reprobed with b-actin antibody to show equal protein loading. Representative results of three
independent experiments are shown.
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Page 8 of 14Figure 4 Plumbagin suppresses CXCR4 through modulation of its mRNA level. A and B, Plumbagin suppresses CXCR4, through lysosomal
but not proteosomal degradation. Cells were treated with indicated concentrations of lactacystin or chloroquine for 1 h at 37°C, followed by
treatment of 5 μM plumbagin for 6 h. Whole-cell extracts were prepared and analyzed by Western blot analysis using antibodies against CXCR4.
The same blots were stripped and reprobed with b-actin antibody to show equal protein loading. Representative results of three independent
experiments are shown. C, Plumbagin suppresses expression of CXCR4 mRNA in MDA-MB-231 cells. Cells were treated with 5 μM plumbagin for
indicated times. Total RNA was isolated and analyzed by RT-PCR assay as described in Materials and Methods. 18S was shown to equal loading
of total RNA. Representative results of three independent experiments are shown. D, Plumbagin inhibits NF-B activation in MDA-MB-231 breast
cancer cells. MDA-MB-231 cells were incubated with indicated concentrations of plumbagin for 2 h. The nuclear extracts were assayed for NF-B
activation by TransAM p65 transcription factor assay kit. E, MDA-MB-231 cells were transiently transfected with an NF-B-luciferase plasmid and
then treated with the indicated concentrations of plumbagin for 2 h. Cell supernatants were thereafter collected and assayed for luciferase
activity as described in Materials and Methods. Representative results of three independent experiments are shown. Results are expressed as fold
activity over the activity of the vector control. Bars indicate standard deviation. * indicates p value < 0.05). F, Plumbagin inhibits binding of NF-
B to the CXCR4 promoter. MDA-MB-231 cells were treated with 5 μM plumbagin for indicated time intervals and the proteins were cross-linked
with DNA by formaldehyde and then subjected to ChIP assay using an anti-p65 antibody with the CXCR4 primer. Reaction products were
resolved by electrophoresis.
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Page 9 of 14Figure 5 Plumbagin suppresses migration of breast and gastric cancer cells. A, The wound-healing assay for evaluating the inhibitory
effect of plumbagin on MDA-MB-231 cell migration. Confluent monolayers of MDA-MB-231 cells were scarred, and repair was monitored
microscopically after 6 h of pre-treatment with 5 μM plumbagin before being exposed to 100 ng/mL CXCL12 for 24 h. Width of wound was
measured at time zero and 24 h of incubation with and without plumbagin in the absence or presence of CXCL12 in RPMI medium containing
1% serum. The representative photographs showed the same area at time zero and after 48 h of incubation. Graphs, mean (n = 3); bars, SE. *, P
< 0.05. B, The wound-healing assay for evaluating the inhibitory effect of plumbagin on AGS cell migration. Confluent monolayers of AGS cells
were scarred, and repair was monitored microscopically after 6 h of pre-treatment with 5 μM plumbagin before being exposed to 100 ng/mL
CXCL12 for 24 h. Width of wound was measured at time zero and 24 h of incubation with and without plumbagin in the absence or presence
of CXCL12 in RPMI medium containing 1% serum. The representative photographs of three independent experiments showed the same area at
time zero and after 48 h of incubation. Graphs, mean (n = 3); bars, SE. *, P < 0.05.
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Page 10 of 14Figure 6 Plumbagin suppresses invasion in breast and gastric cancer cells. A, MDA-MB-231 (2 × 10
5 cells) were seeded in the top-chamber
of the Matrigel. After pre-incubation with or without plumbagin (5 μM) for 6 h, transwell chambers were then placed into the wells of a 24-well
plate, in which we had added either the basal medium only or basal medium containing 100 ng/mL CXCL12 for 24 h. After incubation, they
were assessed for cell invasion as described in Materials and Methods. Columns indicate mean percentage of invaded cells; bars, S.E. *, P < 0.05.
B, AGS (2 × 10
5 cells) were seeded in the top-chamber of the Matrigel. After pre-incubation with or without plumbagin (5 μM) for 6 h, transwell
chambers were then placed into the wells of a 24-well plate, in which we had added either the basal medium only or basal medium containing
100 ng/mL CXCL12 for 24 h. After incubation, the chambers were assessed for cell invasion as described in Materials and Methods. Columns
indicate mean percentage of invaded cells; bars, S.E. *, P < 0.05. Representative results of three independent experiments are shown. C,
Plumbagin suppresses expression of CXCR4 mRNA expression in gastric cancer cells. AGS cells were treated with 5 μM plumbagin for indicated
times. Total RNA was isolated and analyzed by RT-PCR assay as described in Materials and Methods. 18S was shown to equal loading of total
RNA. Representative results of three independent experiments are shown. D, Plumbagin suppresses expression of CXCR4 protein expression in
gastric cancer cells. Cells were incubated with 5 μM plumbagin for indicated times. Whole-cell extracts were prepared and analyzed by Western
blot analysis using antibodies against CXCR4. The same blots were stripped and reprobed with b-actin antibody to show equal protein loading.
Representative results of three independent experiments are shown.
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Page 11 of 14expression in HER2 overexpressing BT474 breast cancer
cells. Our results showed that downregulation of
CXCR4 did not occur through proteolytic degradation
of the receptor but rather through downregulation of
the transcript. Furthermore, suppression of receptor
expression led to downregulation of migration and inva-
sion induced by the ligand CXCL12 in both breast and
gastric cancer cells.
The CXCR4 chemokine receptor has been found to be
overexpressed in different tumors, including breast can-
cer, gastric cancer, ovarian cancer, glioma, pancreatic
cancer, prostate cancer, acute myeloid leukemia, chronic
lymphoblastic leukemia (CLL), B-CLL, melanoma,
cervical cancer, colon carcinoma, rhabdomyosarcoma,
astrocytoma, small-cell lung carcinoma, renal cancer,
and non-Hodgkin’s lymphoma, as compared to normal
cells which show little or no CXCR4 expression
[13,22,40,47-49]. Although it is still unclear what leads to
the overexpression of CXCR4 in tumor cells, studies
point to genetic and microenvironmental factors [50].
PAX3- and PAX7-FKHR gene fusion [51], mutations in
the von Hippel Lindau tumors u p p r e s s o rg e n e[ 5 2 ] ,
hypoxia in the tumor microenvironment [53], NF-B
[44], and inflammatory cytokines such as vascular
endothelial growth factor [54] and tumor necrosis factor
alpha [50], have all been implicated in CXCR4 overex-
pression. Recently, the epidermal growth factor receptor,
c-erbB2, and its encoding gene, HER2/neu,h a v ea l s o
been implicated in the positive regulation of CXCR4
expression at the post-transcriptional level [55,56]. Given
that CXCR4 has been linked with the metastasis of var-
ious cancers and CXCR4 expression has been correlated
with poor prognosis and poor overall patient survival
[57], CXCR4 appears an ideal therapeutic target for the
investigation of novel therapeutic interventions for the
prevention of metastatic cancer.
Our results clearly indicate that plumbagin suppressed
CXCR4 expression in both HER2-lacking and -overex-
pressing breast cancer cells, but had minimal effect on
HER2 expression in BT474 breast cancer cells. Our data
also showed that plumbagin suppressed CXCR4 expres-
sion on various tumor cell lines including gastric cancer,
lung adenocarcinoma, renal cell carcinoma, oral and
hepatocellular carcinoma, thereby indicating that the
effect of plumbagin on CXCR4 is not limited to a single
tumor cell type. The ligand-dependent downregulation
of the CXCR4 receptor by lysosomal degradation is well
documented [40]. Recent reports suggest that degrada-
tion involves atrophin-interacting protein (AIP)-4
mediated ubiquitination and degradation [43]. However,
our data indicate that plumbagin does not downregulate
the CXCR4 through this mechanism. As such, with
downregulation of CXCR4 by plumbagin arguably not
occurring at the post-translational level, we postulated
that the inhibition of CXCR4 expression by this quinine
could occur at the transcriptional level. Indeed, we
found that plumbagin downregulated the expression of
CXCR4 mRNA in breast and gastric cancer cells.
Plumbagin has been previously reported to downregu-
late NF-B activation in various tumor cells [23]. Inter-
estingly, the NF-B binding site has also been identified
in the proximal region of the CXCR4 promoter and pos-
tulated to play a role in CXCR4 expression in human
breast cancer cells [44]. Therefore, it is possible that
downregulation of CXCR4 by plumbagin occurs via the
suppression of NF-B. Indeed, we found that inhibition
of constitutive NF-B activation by plumbagin leads to
downregulation of CXCR4 in MDA-MB-231 cells. The
NF-B mediated regulation of CXCR4 in the tumor
cells was also tested in the virtual system and the pre-
dictions corroborated with the experimental results.
Whether mechanism(s) other than suppression of NF-
B activation are involved in downregulation of CXCR4
by plumbagin, cannot currently be confirmed or ruled
out. Furthermore, besides CXCR4, the activation of NF-
B also induces the expression of various molecules
including cyclooxygenase-2, matrix metallopeptidase-9,
and adhesion molecules such as intracellular adhesion
molecule 1, vascular cell adhesion molecule 1, and
endothelial-leukocyte adhesion molecule 1, all of which
have been linked with cancer cell migration, invasion,
and metastasis [58]. Because plumbagin can inhibit both
DNA binding ability and transcriptional activation of
NF-B ,a ss h o w ni nt h i ss t u d y ,i ti sp o s s i b l et h a tp l u m -
bagin can suppress the expression of other NF-B
regulated molecules as well in breast cancer cells.
We further investigated the effect of plumbagin on
CXCL12-induced migration and invasion of both breast
and gastric cancer cells. We found that preincubation of
cells with plumbagin completely blocked CXCL12-
induced migration and invasion of both breast and gas-
tric cancer cells.
Plumbagin has been shown to inhibit different aspects
of tumor initiation and progression, including prolifera-
tion, invasion, angiogenesis, and metastasis in various
tumor cell lines and animal models [23-30]. Our data
shows for the first time that plumbagin downregulates
expression of CXCR4 in a variety of tumor cells, a key
receptor involved in the cross-talk between tumor cells
and its microenvironment, and thus, that some of the
anti-tumor effects of plumbagin are possibly mediated
through CXCR4 regulation. Further in vivo studies are
being planned to demonstrate the relevance of these
observations to cancer treatment.
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